
Please try another search
By Sam Boughedda
Illumina (NASDAQ:ILMN) announced Thursday that a judge presiding over the Federal Trade Commission's (FTC) challenge of its GRAIL acquisition has ruled in favor of the company.
The ruling is a blow to the FTC, which had been trying to unwind the $7.1 billion proposed acquisition of Grail, a cancer detection test maker.
The FTC believes the deal would harm innovation and boost prices.
However, Illumina said the judge rejected the FTC's position that the deal would adversely affect competition for multi-cancer early detection tests.
"Reuniting Illumina and GRAIL will transform the detection and treatment of cancer by facilitating widespread, affordable access to GRAIL's life-saving Galleri test. This decision is a step toward making that vision a reality," declared Francis deSouza, Chief Executive Officer of Illumina.
Illumina founded GRAIL seven years ago, but it was split off as a separate business for funding and development purposes.
Illumina shares are down over 3% at the time of writing.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.